Bavarian Nordic A/S (BVNRY.PK), Thursday announced an updated guidance for the fiscal year 2024, primarily due to the bulk Mpox vaccine orders secured by the company as well as improved performance in Travel Health.
The company now expects revenue of DKK 5,400 million to DKK 5,800 million and EBITDA of DKK 1,450 million to DKK 1,700 million for the full year.
Currently, Bavarian Nordic's stock is trading at $11.77, down 1.25 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.